Summary
Glenmark's move to start an Onco facility in Argentina is an ACE among business strategies.
Many bigger & more well established Indian pharma have been left wanting in Lat Am.
This move will help Glenmark as 1st mover advantage as well as establish firm foothold in the market.
Current lifestyles and eating habits will only augment the demand for Onco products.
Lat Am is a mine field of opportunities & Glenmark is going to have major chunk of it.
Analysis
LAT-AM is a one of those market which Indian pharma companies have been trying to understand for decades now.
Many have tried & failed.
Indian corporates are full of failure stories in Latin America.
One of the reason is lack of local presence, manufacturing, local community involvement etc...
Glenmark learning from their own mistakes & that of others have made a sensible move here.
Argentina is a better place to conduct business & invest among other countries there.
Serycal accqsition a few years back has played favorably for Glenmark.
Expect Glenamrk to be among top 3 players in Onco space in Lat Am once the local facility starts operations.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
